On the stock market since 2025, it operates in the world of money and finance. It has 9 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 25% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 21% below its peak. The market has trimmed its expectations for the company.
Sales run at $36.9M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 8 buys and 4 sells. Management buying with its own money is usually read as a good sign.
It pays out $2.44 per share each year — regular cash for whoever holds the stock.
A loss of $18.4M against $36.9M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, CNFRZ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CNFRZ is a high-risk stock — not yet profitable, and its future rides on its product catching on.